Bormioli Pharma has recently joined Glass Futures, a UK-based project that aims to develop a low CO2 emission approach to glass production.
The project, which will last ten years, will soon see the opening of a pilot furnace in the UK dedicated to the experimentation and application of these technologies.
"In a celebration year for glass, we are ready to confirm our role as innovators in the industry, with several concrete research and development initiatives," said Andrea Lodetti, CEO of Bormioli Pharma.
"This commitment is all the more important in a sector such as pharmaceuticals, where glass must not only contain, but also protect the therapeutic efficacy, and where the constant increase in production requires a serious rethinking of our responsibilities towards the environment."
Sustainability is a key pillar for Bormioli Pharma, which has committed to manufacturing 50% of its products using materials with low environmental impact by 2025.